Oregon Public Employees Retirement Fund Purchases New Position in Indivior PLC $INDV

Oregon Public Employees Retirement Fund purchased a new stake in shares of Indivior PLC (NASDAQ:INDV) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 28,600 shares of the company’s stock, valued at approximately $1,026,000.

A number of other institutional investors also recently modified their holdings of the business. Oaktree Capital Management LP lifted its stake in shares of Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after buying an additional 246,776,273 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares in the last quarter. Vanguard Group Inc. lifted its stake in Indivior by 57.9% in the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after purchasing an additional 2,008,078 shares in the last quarter. Rubric Capital Management LP lifted its stake in Indivior by 31.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after purchasing an additional 1,117,140 shares in the last quarter. Finally, Newtyn Management LLC lifted its stake in Indivior by 61.1% in the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after purchasing an additional 1,592,982 shares in the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

INDV has been the topic of several recent analyst reports. Northland Securities set a $50.00 target price on shares of Indivior in a research note on Tuesday, January 20th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Finally, Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Indivior currently has a consensus rating of “Buy” and a consensus price target of $39.33.

Insider Activity at Indivior

In related news, Director Stuart A. Kingsley purchased 940 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were purchased at an average price of $31.86 per share, with a total value of $29,948.40. Following the acquisition, the director directly owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This represents a 20.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.74% of the stock is owned by insiders.

Indivior Price Performance

Shares of NASDAQ:INDV opened at $36.54 on Tuesday. The company’s fifty day moving average price is $33.02 and its 200-day moving average price is $33.50. The firm has a market capitalization of $4.46 billion, a price-to-earnings ratio of 18.74 and a beta of 0.90. Indivior PLC has a one year low of $11.06 and a one year high of $41.00.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The firm had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. As a group, equities research analysts expect that Indivior PLC will post 3.35 EPS for the current year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.